The consistent downregulation of LRRN1 across multiple pathological parameters, coupled with its strong inverse correlations with disease progression markers, positions it as a particularly promising candidate for further mechanistic investigation and potential therapeutic targeting in advanced breast cancer. Here, LRRN1 is linked to breast carcinoma.